These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22226711)

  • 1. N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia.
    Lopotová T; Nádvorníková S; Záčková M; Polák J; Schwarz J; Klamová H; Moravcová J
    Leuk Res; 2012 Apr; 36(4):e81-3. PubMed ID: 22226711
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and clinical characteristics of N-terminally truncated WT1 expression in acute myeloid leukemia.
    Ishikawa Y; Kiyoi H; Naoe T
    Leuk Res; 2011 May; 35(5):685-8. PubMed ID: 21256590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs.
    Lopotová T; Polák J; Schwarz J; Klamová H; Moravcová J
    Blood Cells Mol Dis; 2012 Jun; 49(1):41-7. PubMed ID: 22555024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
    Szántó A; Pap Z; Dénes L; Benedek Lázár E; Horváth A; Tunyogi AB; Baróti BÁ; Pávai Z
    Rom J Morphol Embryol; 2015; 56(2 Suppl):703-7. PubMed ID: 26429162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
    Cilloni D; Messa F; Gottardi E; Fava M; Arruga F; Defilippi I; Carturan S; Messa E; Morotti A; Giugliano E; Rege-Cambrin G; Alberti D; Baccarani M; Saglio G
    Cancer; 2004 Sep; 101(5):979-88. PubMed ID: 15329907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
    Na IK; Kreuzer KA; Lupberger J; Dörken B; le Coutre P
    Leuk Res; 2005 Mar; 29(3):343-5. PubMed ID: 15661271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Wilms' tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants.
    Siehl JM; Reinwald M; Heufelder K; Menssen HD; Keilholz U; Thiel E
    Ann Hematol; 2004 Dec; 83(12):745-50. PubMed ID: 15340762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
    Schnittger S; Bacher U; Kern W; Tschulik C; Weiss T; Haferlach C; Haferlach T
    Br J Haematol; 2009 Sep; 146(6):665-8. PubMed ID: 19624538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
    Ruan GR; Qin YZ; Chen SS; Li JL; Ma X; Chang Y; Wang YZ; Fu JY; Liu YR
    Leuk Res; 2006 Sep; 30(9):1159-65. PubMed ID: 16507320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Real-time PCR quantification of bcr/abl chimera and WT1 genes in chronic myeloid leukemia].
    Fujii T; Inoue S; Karashima T; Masumoto M; Yamaguchi H; Kinoshita S; Muta K; Hamasaki N
    Rinsho Byori; 2003 Sep; 51(9):839-46. PubMed ID: 14560650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia.
    Spanaki A; Linardakis E; Perdikogianni C; Stiakaki E; Morotti A; Cilloni D; Kalmanti M
    Leuk Res; 2007 Apr; 31(4):570-2. PubMed ID: 16876863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation.
    Uzunel M; Ringdén O
    Bone Marrow Transplant; 2004 Jan; 33(1):47-52. PubMed ID: 14704656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of detecting WT1 expression in childhood acute leukemias.
    Hu SY; Gu WY; Chen ZX; Wang XL; Cen JN; He HL; Chai YH; Chen CS
    Pediatr Hematol Oncol; 2010 Nov; 27(8):581-91. PubMed ID: 20863155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukemia effects of Wilms' tumor 1 protein-specific cytotoxic T lymphocytes in patients with chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Wang ZD; Li D; Huang XJ
    Chin Med J (Engl); 2010 Apr; 123(7):912-6. PubMed ID: 20497687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Co-expression of major and minor bcr/abl in chronic myelogenous leukemia].
    Sugimoto T; Murayama T; Mizuno I; Hato A; Imoto S; Saigo K; Kumagai S; Nishimura R; Koizumi T
    Rinsho Ketsueki; 2003 Mar; 44(3):139-43. PubMed ID: 12722339
    [No Abstract]   [Full Text] [Related]  

  • 17. WT1 isoform expression pattern in acute myeloid leukemia.
    Luna I; Such E; Cervera J; Barragán E; Ibañez M; Gómez-Seguí I; López-Pavía M; Llop M; Fuster O; Dolz S; Oltra S; Alonso C; Vera B; Lorenzo I; Martínez-Cuadrón D; Montesinos P; Senent ML; Moscardó F; Bolufer P; Sanz MA
    Leuk Res; 2013 Dec; 37(12):1744-9. PubMed ID: 24211094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
    Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
    Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy.
    Cilloni D; Saglio G
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):37-41. PubMed ID: 12783374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood.
    Popova EY; Claxton DF; Lukasova E; Bird PI; Grigoryev SA
    Exp Hematol; 2006 Apr; 34(4):453-62. PubMed ID: 16569592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.